Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/175248
Title: | A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART |
Author: | Gómez, Carmen Elena Perdiguero, Beatriz García Arriaza, Juan Cepeda, Victoria Sánchez Sorzano, Carlos Oscar Mothe, Beatriz Jiménez, José Luis Muñoz Fernández, María Ángeles Gatell, José M López Bernaldo de Quirós, Juan Carlos Brander, Christian García Alcaide, Felipe Esteban, Mariano |
Keywords: | VIH (Virus) Vacunes antivíriques Cèl·lules T HIV (Viruses) Viral vaccines T cells |
Issue Date: | 6-Nov-2015 |
Publisher: | Public Library of Science (PLoS) |
Abstract: | Trial Design: Previous studies suggested that poxvirus-based vaccines might be instrumental in the therapeutic HIV field. A phase I clinical trial was conducted in HIV-1-infected patients on highly active antiretroviral therapy (HAART), with CD4 T cell counts above 450 cells/mm3 and undetectable viremia. Thirty participants were randomized (2:1) to receive either 3 intramuscular injections of MVA-B vaccine (coding for clade B HIV-1 Env, Gag, Pol and Nef antigens) or placebo, followed by interruption of HAART. Methods: The magnitude, breadth, quality and phenotype of the HIV-1-specific T cell response were assayed by intracellular cytokine staining (ICS) in 22 volunteers pre- and post-vaccination. Results: MVA-B vaccine induced newly detected HIV-1-specific CD4 T cell responses and expanded pre-existing responses (mostly against Gag, Pol and Nef antigens) that were high in magnitude, broadly directed and showed an enhanced polyfunctionality with a T effector memory (TEM) phenotype, while maintaining the magnitude and quality of the pre-existing HIV-1-specific CD8 T cell responses. In addition, vaccination also triggered preferential CD8+ T cell polyfunctional responses to the MVA vector antigens that increase in magnitude after two and three booster doses. Conclusion: MVA-B vaccination represents a feasible strategy to improve T cell responses in individuals with pre-existing HIV-1-specific immunity. |
Note: | Reproducció del document publicat a: https://doi.org/10.1371/journal.pone.0141456 |
It is part of: | PLoS One, 2015, vol. 10, num. 11, p. e0141456 |
URI: | http://hdl.handle.net/2445/175248 |
Related resource: | https://doi.org/10.1371/journal.pone.0141456 |
ISSN: | 1932-6203 |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
693527.pdf | 1.47 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License